MT1DP and cancer: Furthermore, genetic alterations (e.g., single nucleotide polymorphisms in gene promoters [46], [47], [48] and chromosomal translocations leading to the production of aberrant TFs [49]) that increase the risk of cancer initiation and progression could determine increased sensitivity of cancer cells to MTM-A.